Lastname    Password   

The largest participative network on microencapsulation

20th Microencapsulation Industrial Convention

Nantes, France
April 10-13, 2017

More information, click here

25th International Conference on Bioencapsulation

La Chapelle sur Erdre (Nantes), France
July 3-6, 2017

More information, click here

9th Training School on Microencapsulation

Berlin, Germany
September 11-14, 2017

More information, click here

3th Latin-America Symposium on Microencapsulation

Pucon, Chile
November 27-29, 2017

More information, click here

Microencapsulation News


Publ. : 02 OCT. 2017 - Deadline : 27 AUG. 2018
BIOBARRIERS 2018 - 27 – 29 August 2018 in Saarbrücken, Germany

The 12th International Conference and Workshop on Biological Barriers is an international scientific event, organized every two years and receiving co stantly 200+ registered attendees from all over the world. In the focus of BioBarriers 2018 are human cell and tissue models for facilitating clinical translation of new drugs and delivery systems, especially in the context of infectious diseases. Moreover, we will discuss innovative concepts and materials, also capable to overcome non-cellular diffusion barriers such as mucus or bacterial biofilms, concluding the conference with sessions on extracellular vesicles and advanced nanomedicines for non-invasive delivery of macromolecular biopharmaceuticals. Target audiences are early stage researchers as well as experienced scientists and professionals from academia and the pharmaceutical industry.

More information

Publ. : 01 OCT. 2017 - Deadline : 01 DEC. 2017
Microencapsulated lipid nanoparticles for pulmonary delivery of biopharmaceutical agents

Thesis 2017 by Diana Patricia Rodrigues Gaspar UNIVERSIDADE DE LISBOA FACULDADE DE FARMÁCIA A key point in the administration of biopharmaceutica s is the recognition of appropriate, effective, safe and biocompatible nanocarriers allowing overcoming extracellular and intracellular biological barriers without loss of drug stability and adequate therapeutic response at the target sites. Since their description by Rainer Müller in the early 1990’s, solid lipid nanoparticles (SLN) have been developed as an effective colloidal drug carrier. Under optimized conditions, SLN can be produced for the entrapment of lipophilic or hydrophilic drugs with the essential requirements for an optimum nanoparticulate carrier. Its colloidal size and the controlled release behaviour allow protection and management when administered by parenteral and non-parenteral routes (e.g., oral, nasal and pulmonary). The pulmonary route has gained interest to the non-invasive administration of biopharmaceuticals on account of the promising anatomical features of the lung, particularly its large absorptive epithelial surface area, low thickness and avoiding the first-pass effect. The lung region where the particles are deposited depends on their aerodynamic diameter. The complex structure of the respiratory tree and the natural defence mechanisms of the lung are fundamental aspects for the design of a proper pulmonary delivery system. Although pulmonary delivery of nanoparticles has an unquestionable interest, it still requires a complex setup and an aerosolization technique, due to their low inertia and small size, which hindering the deposition in the lung, facilitating the exhalation with air. A promising alternative is the formulation of nanoparticles in inhalable microspheres that ensure their release after pulmonary administration. Microspheres have recently been proposed for pulmonary inhalation as dry powders, since they can be designed to achieve appropriate morphological and aerodynamic characteristics. Previous studies have shown that polymeric nanocarriers loaded in microparticulate systems present a great potential for pulmonary delivery of therapeutic macromolecules and genetic material. These microspheres act only as inert vehicles of the nanoparticles, which remain unaltered after the spray-drying process, not affecting the properties or the release profile of the encapsulated active agents, thus constituting a suitable microparticulate carrier for the pulmonary delivery of drug-containing nanoparticles

More information

Publ. : 30 JULY 2017 - Deadline : 30 OCT. 2017

CONTENT • Our oral drug delivery services portfolio - Customized release profiles with EUDRAGIT® • Our laboratory capabilities - Formulation an application labs • Our liposome technology and know-how - Lipid-based drug formulations • Two technical forums we host at Controlled Release Society CRS 2017 • Challenges of developing and manufacturing complex formulations - Article on the MedicineMaker • Bioavailibility & solubility: new approaches to enhance drug performance - Article on Drug Development & Delivery • Our license for handling of controlled substances • Our 2017 seminar program

More information

Send information to be included in the news to

including a short title, a description of 5-10 lines, a deadline, a link (email or url), your name
We ask you before to send your request to register on the BRG